Assessment and Treatment of Patients with Type 2 Myocardial Infarction and Acute Non-Ischemic Myocardial Injury

Running Title: DeFilippis et al.; Type 2 Myocardial Infarction

Andrew P. DeFilippis, MD, MSc1,2; Andrew R. Chapman, MD, PhD3;
Nicholas L. Mills, MD, PhD3,4; James A. de Lemos, MD5;
Armin Arbab-Zadeh, MD, MPH, PhD2; L. Kristin Newby, MD, MHS, FACC, FAHA6;
David A. Morrow, MD, MPH7

1Division of Cardiovascular Medicine, Department of Medicine, University of Louisville School of Medicine, Louisville, KY; 2Johns Hopkins University, Baltimore, MD; 3BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK; 4Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK; 5Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; 6Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; 7Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

Address for Correspondence:
Andrew P. DeFilippis, MD, MSc
550 South Jackson Street
ACB Third Floor
Louisville, Kentucky, 40202
Tel: 1-410-310-0311
Fax: 1-502-852-8070
Email: APDeFi01@louisville.edu
Abstract

While coronary thrombus overlying a disrupted atherosclerotic plaque has long been considered the hallmark and the primary therapeutic target for acute myocardial infarction (MI), multiple other mechanisms are now known to cause or contribute to MI. It is further recognized that a myocardial infarction (MI) is just one of many types of acute myocardial injury. The Fourth Universal Definition of Myocardial Infarction (UDMI) provides a taxonomy for acute myocardial injury, including five subtypes of MI and non-ischemic myocardial injury. The diagnosis of MI is reserved for patients with myocardial ischemia as the cause of myocardial injury, whether due to acute atherothrombosis (type 1 MI) or supply/demand mismatch without acute atherothrombosis (type 2 MI). Myocardial injury in the absence of ischemia is categorized as acute or chronic non-ischemic myocardial injury. However, optimal evaluation and treatment strategies for these etiologically distinct diagnoses have yet to be defined. Herein, we review the epidemiology, risk factor associations, and diagnostic tools that may assist in differentiating between non-ischemic myocardial injury, Type 1 MI, and Type 2 MI. We identify limitations, review new research, and propose a framework for the diagnostic and therapeutic approach for patients who have suspected MI or other causes of myocardial injury.

Key Words: Myocardial infarction; myocardial injury; type 2 myocardial infarction; acute non-ischemic myocardial injury

Non-Standard Abbreviations and Acronyms

CAD – coronary artery disease
CI – confidence interval
CTA – computed tomography angiography
cTN – cardiac troponin
CVD – cardiovascular disease
ECG – electrocardiogram
HR – hazard ratio
ICD – International Classification of Disease
IQR – intra-quartile range
IVUS – intravascular ultrasound
MACE – major adverse cardiovascular event
MI – myocardial infarction
MINOCA – myocardial infarction with no obstructive coronary atherosclerosis
MRI – magnetic resonance imaging
OCT – optical coherence topography
OxPL – oxidized phospholipid
PCI – percutaneous coronary intervention
PET – positron emission tomography
PLG – plasminogen
RR – risk ratio
SCAD – spontaneous coronary dissection
SPECT – single-photon emission computerized tomography
UDMI – Universal Definition of Myocardial Infarction
URL – upper reference limit
Introduction

Myocardial infarction (MI) is defined pathologically as myocardial cell death due to prolonged myocardial ischemia (inadequate oxygen supply to the myocardium). Each year, over 8 million Americans present to the hospital with signs and symptoms suggestive of acute MI.\(^1\) Approximately 700,000 are ultimately diagnosed with MI.\(^1,2\) While coronary thrombus overlying a disrupted atherosclerotic plaque remains the hallmark and primary therapeutic target for MI, multiple other mechanisms are now known to contribute to MI and non-ischemic causes of myocardial injury (\textbf{Table 1, Supp. Table 1, Fig. 1}); however, optimal diagnostic and treatment strategies for patients with myocardial injury due to these non-thrombotic mechanisms have yet to be defined.\(^3,4\)

Over the last decade, cTn assays have become increasingly sensitive, identifying a rising number of patients with previously unrecognized myocardial injury.\(^5,6\) Although cTn is highly specific for myocardial injury, it does not differentiate between the etiologically diverse types of MI or non-MI causes of myocardial injury, which may necessitate different treatment strategies.\(^3,4\) The Fourth Universal Definition of MI (UDMI) recognizes five types of MI, and acute and chronic non-ischemic myocardial injury as distinct clinical entities (\textbf{Table 1, Supp. Table 1, Fig. 1}).\(^4\) However, the optimal approach to classify patients with acute myocardial injury into these etiological categories remains uncertain.

Clinically actionable diagnosis of acute MI subtypes and non-ischemic myocardial injury is essential to foster optimal treatment and outcomes for these patients. Herein, we review evidence regarding the prevalence and outcome of patients classified according to the UDMI, and propose a practical approach to the assessment and management of patients presenting with myocardial injury, with a focus on type 2 MI and non-ischemic myocardial injury.
Universal Definition of Myocardial Infarction

In 2007, a consortium, including the European Society of Cardiology, the American College of Cardiology Foundation, the American Heart Association, and the World Heart Federation, aimed to bring consensus to the diagnosis of MI, and proposed a classification system based on etiology. Advances in both diagnostic tools and understanding of the many underlying mechanisms of myocardial injury prompted subsequent revisions that have culminated in the Fourth UDMI. The UDMI defines myocardial injury based on elevation of cTn concentration, with at least one value >99th percentile upper reference limit derived from a normal reference population. Myocardial injury is a broad diagnostic category, under which multiple possible mechanisms are considered (Fig. 1). Myocardial injury may be acute, manifested as dynamic changes in cTn concentration over serial measurements, or chronic, in which concentrations are stable or change minimally over serial measurement (Fig. 1). Among patients with acute myocardial injury in whom there are symptoms of myocardial ischemia, signs of ischemia on the ECG (ST-segment changes or the development of pathological Q waves), or evidence of a new regional wall motion abnormality, the diagnosis of acute MI is applied. MI is further subclassified by suspected pathophysiology. Type 1 MI is a primary coronary arterial event due to atherothrombotic plaque rupture or erosion. Type 2 MI occurs secondary to an acute imbalance in myocardial oxygen supply and/or demand without atherothrombosis. This imbalance may be due to reduced myocardial perfusion in the context of fixed coronary atherosclerosis (without plaque disruption), coronary artery spasm, microvascular dysfunction, coronary embolism, dissection, or systemic causes such as hypoxemia, anemia, hypotension, or bradyarrhythmia, or increased myocardial oxygen demand due to tachyarrhythmia or severe hypertension. The UDMI also identifies MI types 3-5, in the setting of sudden cardiac death.
without circulating biomarker evaluation or related to revascularization procedures. Although important, these classifications are not the focus of this manuscript (Supp Table 1). Myocardial infarction with no obstructive coronary atherosclerosis (MINOCA) is a classification independent from the UDMI and includes patients with Type 1 and Type 2 MI.

We will refer to acute myocardial injury in the absence of MI as acute non-ischemic myocardial injury throughout this manuscript. Persistently elevated cTn levels that do not demonstrate a dynamic rising and/or falling pattern as seen in acute MI or acute non-ischemic myocardial injury are categorized as chronic myocardial injury. Both structural cardiac abnormalities (e.g., left ventricular hypertrophy, left ventricular dysfunction) and non-cardiac conditions (e.g., diabetes, chronic kidney disease) may contribute to chronic myocardial injury.

While chronic myocardial injury is important, this manuscript is focused on acute MI and acute non-ischemic myocardial injury (Table 1).

**Prevalence of Type 2 MI and Non-Ischemic Myocardial Injury**

Among studies using the 2007 and/or 2012 UDMI, the reported prevalence of type 2 MI ranged from 2-58% of patients with MI (Table 2). Variation in type 2 MI prevalence was also observed between sites in the same study (0-13%). This remarkable variation is likely influenced by differences in the patient populations studied, sensitivity and diagnostic thresholds of the cTn assays used, the rate and types of additional cardiac investigation performed, and limitations of diagnostic criteria and the interpretation of these criteria by adjudicators of MI subtypes (Table 2). For example, the prevalence of type 2 MI among patients presenting to an emergency room for evaluation of suspected MI has ranged from 26-58% versus only 3-7% of MIs among patients admitted to an intensive care unit or enrolled in a clinical trial for acute MI. The proportion of cTn elevations that are adjudicated as acute non-ischemic myocardial injury varies
substantially by the population studied and has been reported to be greater than the proportion of cTn elevations that are adjudicated as MI (any type) (Table 2).

Type 2 MI may arise in the context of various acute medical and surgical conditions that are similarly associated with non-ischemic myocardial injury, making the differentiation between type 2 MI and acute non-ischemic myocardial injury challenging in common clinical settings. Some investigators have simply reported the prevalence and prognosis of all patients with any evidence of myocardial injury that is not due to plaque rupture and coronary thrombosis. Wong and colleagues evaluated 1021 consecutive patients admitted to an urban hospital who had one or more measurements of cTn. 31% had an elevated cTn value, 62% of which were adjudicated as secondary to a cause other than an acute coronary syndrome (i.e., type 1 MI).

Differentiating myocardial injury sub-types is challenging. In a study of cases that were previously classified as acute MI at eight Swedish hospitals in 2011, the kappa statistic for agreement on the diagnosis of type 1 MI, type 2 MI, MI types 3–5, “multifactorial,” and “non-ischemic” was poor (K=0.55). However, this study only included cases diagnosed as an acute MI by the treating physician; therefore, it is not representative of the general pool of myocardial injury patients. In fact, one would expect that only the most challenging cases of “multifactorial” and “non-ischemic” myocardial injury would be available for adjudication since more typical cases would not be classified as acute MI by the treating physician; thus not part of this study. In contrast, in a study that included a broader spectrum of patients presenting to a regional cardiac center in the United Kingdom with an elevated cTn, the investigators reported a kappa was 0.92 for study cardiologists and 0.87 for study internists in diagnosing type 1 MI, type 2 MI, and myocardial injury. Both studies based classification on the third UDMI, and data on adjudication agreement for sub classification of myocardial injury events via the Fourth UDMI
are not yet available. Additional refinement of clinical criteria to aid in discriminating type 2 MI and non-ischemic myocardial injury would be advantageous if achieved.

Establishing specific thresholds of various triggers as “causal” of a type 2 MI has been proposed as a strategy to improve consistency in diagnosis.\textsuperscript{14} However, such an approach is limited by differences in individual patient vulnerability to myocardial injury. For example, a tachyarrhythmia at 150 beats per minute is unlikely to cause myocardial injury in a 35 year old elite athlete with no structural heart disease. However, the same tachyarrhythmia in a 75 year old with multiple fixed flow limiting coronary stenosis and myocardial hypertrophy may cause significant myocardial injury.

Additional methodological research is necessary, focusing on optimizing adjudication criteria for type 2 MI and acute non-ischemic myocardial injury using the Fourth UDMI. The goal of such research should be not only within-study agreement, but also generalizability to other studies populations.

**Characteristics of Patients with Type 2 Myocardial Infarction**

Data on the characteristics of different myocardial injury types are only available for studies that utilize prior versions of the UDMI. While data may differ when utilizing the Fourth UDMI, given the similar taxonomy we believe these data are instructive and relevant to Fourth UDMI definitions. In most studies, patients classified as having a type 2 MI were older, more often female, and had more comorbidities and lower peak cTn levels than patients with type 1 MI.\textsuperscript{9-11, 14-17, 20-22, 24, 25, 27} In one study, those classified as having type 2 MI had similar ages, sex, and risk factor distribution as those with non-ischemic myocardial injury.\textsuperscript{16} Further, the prevalence of coronary artery disease (CAD) among those who received angiography was approximately 50% in both type 2 MI and non-ischemic myocardial injury.\textsuperscript{16} In another study, among patients
selected for cardiac catheterization, 45% of those with type 2 MI and 12% with type 1 MI had no coronary lesions $\geq 50\%$ on angiography. Hypertension, arrhythmias, infection, severe anemia, surgery, renal failure, and heart failure have all been associated with type 2 MI, and have been designated as “causal” by physician adjudication panels in various studies. Many of these causes have been similarly associated with and designated as “causal” of acute non-ischemic myocardial injury.

**Outcomes**

**Mortality**

In most studies, both short and long-term mortality were higher among patients with type 2 MI or myocardial injury compared with type 1 MI (Table 2, Fig. 2). Differences in type 2 MI mortality between studies are likely explained by differences in patient selection. For example, the higher mortality (29%) of type 2 MI in one study may be explained by the exclusion of participants receiving percutaneous coronary intervention (PCI) who may have a more favorable prognosis than those not receiving PCI. Predictors of poor survival among patients with Type 2 MI include older age, female sex, heart failure, shock, and the presence of CAD. Mortality rates for non-ischemic myocardial injury are similar to those for type 2 MI in most studies (Table 2, Fig. 1). Findings from analyses aiming to determine whether the higher prevalence of comorbidities among those with type 2 MI or non-ischemic myocardial injury explains higher mortality in type 2 versus type 1 MI have been inconsistent. In a study of 2165 consecutive patients with cTn elevation, the higher mortality among participants with type 2 vs type 1 MI (risk ratio [RR] 2.15, 95% confidence interval [CI] 1.82-2.55) was attenuated, but remained significant (RR 1.51, 95% CI 1.21-1.87) in a multivariable model incorporating age, sex, renal function, hemoglobin, diabetes, hypertension, CAD, stroke,
peripheral vascular disease, and smoking.\textsuperscript{24} These findings were corroborated by others who reported that adjusting for age, sex, and multiple clinical and laboratory findings had little impact on the higher mortality associated with type 2 MI compared with type 1 MI (hazard ratio [HR] attenuated from 2.0 to 1.8).\textsuperscript{12,15} However, these studies are all limited by the investigators’ ability to identify and account for all relevant confounders of the relationship between type 2 MI and mortality. In contrast, in an analysis of the SWEDEHEART registry, the risk associated with type 2 MI versus type 1 MI was attenuated from a HR of 1.8 to 1.03 with adjustment for background characteristics and treatments.\textsuperscript{27}

Others have demonstrated that coronary angiography is performed less frequently in patients with type 2 MI or acute non-ischemic myocardial injury compared with type 1 MI.\textsuperscript{12,14,21} This observation likely reflects the relative lack of proven efficacy of PCI in type 2 MI and non-ischemic myocardial injury, but also raises the possibility that differences in treatment could contribute to differences in mortality between types of MI and non-ischemic myocardial injury. It is important to appreciate that these observational studies cannot account for the clinical conditions that resulted in patients with type 2 MI or acute non-ischemic myocardial injury receiving or not receiving coronary angiography; therefore, they should not be used as justification for recommending invasive evaluation in type 2 MI or acute non-ischemic myocardial injury patients. Whether treatments administered or not administered to patients with type 2 MI and non-ischemic myocardial injury contribute to worse outcomes remains unknown and will require prospective trials.

\textit{Major Adverse Cardiovascular Events}

The risk profile of patients with type 2 MI and non-ischemic myocardial injury differs significantly from patients with type 1 MI; they are at higher risk of death from non-
cardiovascular causes. This competing risk of non-cardiovascular death is important, and may explain some of the observed variability in MACE rates in observational datasets to date. In a study of consecutive hospitalized patients with myocardial injury, MACE rates were similar between participants with type 2 MI (30%), type 1 MI (33%), and non-ischemic myocardial injury (31%). In a multivariable model that attempted to account for competing risk of death between sub-classifications, the adjusted risk of five-year MACE was lower in type 2 MI versus type 1 MI (RR 0.74, 95% CI 0.62-0.88). The higher mortality but similar or lower MACE rate among type 2 MI and non-ischemic myocardial injury versus type 1 MI suggests this risk of death is driven by patient comorbidities rather than complications of ischemia or necrosis. This hypothesis is further supported by the fact that high cardiovascular and non-cardiovascular mortality in type 2 MI and non-ischemic myocardial injury occurs despite quantitatively less myocardial injury versus type 1 MI, as reflected by a lower median peak cTn level (Fig. 2 and 3, Table 2).

Hospital Length of Stay and Readmission Rates

In a United States Veterans Affairs cohort, the duration of hospital stay among patients with type 2 MI (median 7, intra-quartile range [IQR] 2-17 days) and non-ischemic myocardial injury (10, IQR 4-23 days) was double compared with type 1 MI (4, IQR 2-7 days), but readmission rates over an average of 1.8 years of follow up were similar (type 2 MI 43%, type 1 MI 42%, and non-ischemic myocardial injury 46%).

Assessment and Investigation

The Fourth UDMI provides a framework for classification of myocardial injury by etiology. However, due to significant overlap of risk factors and diagnostic criteria, timely and accurate diagnosis of etiologically distinct types of myocardial injury is challenging in clinical practice.
While there is no gold standard that discriminates type 2 MI and non-ischemic myocardial injury from each other and from type 1 MI, several diagnostic modalities are commonly employed to assist with diagnosis and guide therapy.

**Symptoms**

The UDMI notes the following symptoms, in various combinations, as associated with myocardial ischemia: chest, upper extremity, mandibular, or epigastric discomfort, and dyspnea or fatigue during exertion or at rest.\(^4\) While data on duration of symptoms is lacking, experts have suggested a minimum of 10 minutes for symptoms to be considered consistent with MI. However, these symptoms, regardless of duration, are not specific for myocardial ischemia and MI may occur with atypical symptoms or even without symptoms at all.\(^4\) For example, an assessment of over 4 million patients with MI found that 33% did not report chest pain on presentation.\(^34\) A cardiac catheterization study of patients with a history of angina and known obstructive CAD reported denial of all typical symptoms of ischemia, including chest pain, in >30% of patients during ECG-confirmed ischemia induced via prolonged coronary balloon inflation.\(^35\) Symptoms atypical for myocardial ischemia are more common in diabetics, the elderly, and women,\(^36\) a combined demographic that accounts for the majority of patients ultimately diagnosed with acute MI.\(^37-40\) Moreover, surveillance studies have found up to 45% of all MIs to be silent or unrecognized with mortality rates similar to recognized MIs\(^41,42\)

Studies comparing the prevalence of ischemic symptoms among patients with type 1 MI versus type 2 MI or non-ischemic myocardial injury are small and limited by classification bias due to symptomatology influence on myocardial injury type classification. Among studies of physician adjudication of myocardial injury type, prevalence of chest pain ranges significantly from 49-93% for type 1MI, 9-62% for type 2 MI, 0-27% for non-ischemic myocardial injury,
and 13% for patients with multifactorial or indeterminate causes of elevated cTn. Dyspnea was more prevalent in type 2 MI (12-46%) and non-ischemic myocardial injury (33%) as compared with type 1 MI (4-10%)

Therefore, the presence or absence of various signs and symptoms may increase or decrease the odds of acute ischemia. However, these signs and symptoms vary in prevalence between types of myocardial injury, none are diagnostic of acute ischemia (MI), and they cannot reliably differentiate types of myocardial injury.

Electrocardiogram

Dynamic ST-segment changes are indicative of significant ongoing, acute myocardial ischemia, and can identify patients who may benefit from urgent invasive evaluation. However, dynamic ST-segment changes are found in only a minority of patients with MI, and cannot reliably discriminate type 1 from type 2 MI (Supplemental Table 2). Among 1335 patients with suspected ST-segment elevation MI undergoing emergent cardiac catheterization, 14% had no evidence of intra-coronary thrombosis. More than a third of these patients had elevated cardiac biomarkers consistent with myocardial necrosis. ST-segment depression is also observed in a significant portion of patients with type 2 MI (25-53%), and in some studies occurs more frequently than among patients with type 1 MI (18-52%).

Cardiac Biomarkers

While significant differences in the distribution of baseline or peak cTn levels are evident in several studies, overlapping ranges limit the use of cTn levels to accurately differentiate between etiologies of myocardial injury (Fig. 3). For example, although Nestelberger et al. found a statistically significant differences in the median baseline and 1-hour change between patients with type 2 MI with or without the presence of CAD, patients with type 1 MI, and those with
non-ischemic myocardial injury, significant overlap in the interquartile ranges for both measures was evident. Furthermore, although peak cTn values were higher in type 1 versus type 2 MI, both the absolute cTn level and the change over time provided poor discrimination for type 1 from type 2 MI (area under the receiver operator characteristic curve, 0.51-0.62).

**Invasive Imaging**

Coronary angiography is considered the gold standard for defining coronary anatomy and is used widely to identify patients with evidence of plaque rupture and coronary thrombosis among patients with suspected type 1 MI. While the UDMI acknowledges that coronary angiography may aid in the distinction between type 1 MI, type 2 MI, and acute non-ischemic myocardial injury, it is emphasized that coronary angiography is not always clinically indicated or required (Fig. 4). Despite common clinical use of invasive angiography for this purpose, rigorous diagnostic studies for differentiating thrombus from stable fibrotic plaque are few and reveal low sensitivity for identifying coronary thrombosis. As such, there are limited quantitative data on the efficacy of coronary angiography for differentiation of type 1 from type 2 MI. Specificity for identifying highly probable thrombotic lesions was 99-100% for spherical, ovoid, or irregular filling defects and intraluminal staining, but sensitivity was very low for all tested angiographic characteristics (17-60%). Using postmortem angiography, Levin and colleagues showed that 79% of lesions with complex morphology were associated with plaque rupture, plaque hemorrhage, superimposed partially occluding thrombus, or recanalized thrombus. However, postmortem angiography on a non-beating heart is of questionable relevance to clinical angiography. In a cohort of 52 participants, utilizing angioscopy to classify the presence or absence of coronary thrombus, angiography was 19% sensitive and 100% specific for coronary thrombus. Advanced invasive coronary imaging techniques, such as intravascular ultrasound...
(IVUS) and optical coherence topography (OCT), have also been used to define plaque disruption and intra-coronary thrombus. Among patients with acute MI and a culprit lesion identified by conventional angiography, imaging consistent with plaque disruption was found in 73% by OCT, 47% by angioscopy, and 40% by IVUS. However, others have shown via pathology, OCT, angioscopy, and IVUS that up to 79% of plaque disruptions are clinically silent and heal without obstructive coronary thrombosis and resultant acute MI. Therefore, plaque disruption alone does not provide unequivocal evidence of type 1 MI, and thrombus formation and resolution as a consequence of endogenous fibrinolysis may add to diagnostic uncertainty.

While OCT and angioscopy have moderate sensitivity and excellent specificity for the identification of plaque disruption and coronary thrombosis, the expense, invasiveness required, and the high level of expertise needed to perform these techniques currently precludes routine use.

**Non-Invasive Imaging**

Non-invasive imaging may be helpful for differentiating type 1 MI from other causes of myocardial injury by 1) directly assessing the coronary arterial anatomy for evidence of atherosclerotic disease and thrombus, 2) evaluating the presence and pattern of myocardial edema, inflammation, or scar, and 3) identifying non-coronary cardiac pathologies associated with myocardial injury.

**Computed Tomography Coronary Angiography**

Due to its superior spatial resolution over other modalities such as magnetic resonance imaging (MRI), coronary computed tomography angiography (CTA) currently is best suited to non-invasively assess the coronary anatomy. CTA can detect small atherosclerotic plaques, and its assessment of the coronary anatomy correlates well with intravascular ultrasound. However,
thrombus is difficult to differentiate from non-calcified atherosclerotic plaque by CTA.\textsuperscript{52} Although thrombotic vascular occlusions can be detected by CT, these cases rarely create diagnostic challenges. Plaque ruptures may be seen by CTA; however, sensitivity is modest when compared with intravascular ultrasound.\textsuperscript{53} The value of CTA for detecting culprit coronary arterial lesions may increase with further refinements of the technology, e.g., improved spatial resolution.\textsuperscript{54} Since atherosclerotic disease is a requisite for type 1 MI, absence of coronary atherosclerotic disease by CTA largely excludes this possibility and suggests type 2 MI or non-ischemic myocardial injury in the setting of cTn elevation.\textsuperscript{55}

Spontaneous coronary dissection (SCAD) is an increasingly recognized entity which is suspected to be the cause of acute MI in more than one third of women under 50 years old.\textsuperscript{56} CTA may be useful to identify patients with SCAD and thus differentiate type 1 versus type 2 MI due to SCAD.\textsuperscript{57}

\textbf{Structural and Functional Imaging}

Echocardiography is widely available and relatively inexpensive. While echocardiography can detect abnormalities in myocardial thickening and motion within minutes of the onset of ischemia, its sensitivity is limited in individuals with small myocardial insults.\textsuperscript{58} Detection of specific patterns of myocardial contractile abnormalities (e.g., regional wall motion abnormalities in a coronary territory or characteristics of stress cardiomyopathy) may support specific types of myocardial injury; however, myocardial dysfunction in a specific coronary distribution is only supportive of MI if it is known to be an acute change, a determination that is often challenging in clinical practice. Furthermore, type 2 MI (e.g., due to dissection, spasm, embolization, or supply/demand mismatch in the setting of fixed obstructive CAD) may result in regional wall motion abnormalities similar to type 1 MI, limiting the use of echocardiography to
differentiate between some type 2 MIs and type 1 MIs. Echocardiography may be useful for detecting non-coronary pathologies of myocardial injury, such as severe aortic stenosis or cardiomyopathy.

Myocardial perfusion imaging may identify patterns of myocardial perfusion abnormalities that allow insights into the mechanism of the insult. Regional perfusion abnormalities, particularly within specific vascular distributions, increase the probability of type 1 MI or non-atherothrombotic coronary abnormalities (e.g., coronary dissection, supply/demand mismatch in the setting of fixed obstructive CAD) resulting in type 2 MI, whereas diffuse myocardial perfusion abnormalities or normal perfusion may suggest more systemic insults from ischemic or non-ischemic myocardial injury. Myocardial perfusion imaging may be performed with contrast echocardiography, single-photon emission computerized tomography (SPECT), positron emission tomography (PET), CT, or MRI.

Cardiac MRI is a non-invasive imaging modality for assessing myocardial dysfunction, and in conjunction with delayed contrast enhancement, can differentiate between acute and chronic myocardial injury via the presence of tissue edema. Ischemia-induced myocardial injury typically extends from the sub-endocardium to the epicardium, while non-ischemic myocardial injury can be seen at the epicardium, mid-wall, or the insertion points of the right ventricle. MRI is not well suited to assess the coronary arterial anatomy because of its limited spatial resolution with standard protocols. At specialized centers, dedicated sequencers may allow assessment of coronary arterial characteristics, including high-risk plaque and thrombus. A major strength of MRI is its capability to identify conditions associated with myocardial injury not related to MI. Among patients presenting with suspected acute MI in whom obstructive CAD was excluded, MRI found evidence of acute myocarditis in 15-75% of patients with an
accuracy of 78-83% compared with histology / clinical diagnosis. Cardiomyopathies, particularly stress cardiomyopathy, are well characterized by MRI.

**Practical Approach to the Assessment and Treatment of Patients with Myocardial Injury**

Among patients with myocardial injury that is potentially acute and possibly due to myocardial ischemia, many time-sensitive diagnostic and therapeutic decisions must be made to provide optimal care, including judicious use of advanced testing. Specifically, classification is important for the timely initiation of evidence-based therapies for patients with type 1 MI, including anti-platelet and anti-coagulation therapies, and coronary revascularization. However, use of diagnostic imaging modalities that employ contrast agents must be weighed against the risk of nephropathy, radiation exposure, or nephrogenic systemic fibrosis, while the potential benefit of anti-thrombotic therapies must consider the risk of bleeding. Balancing the risk and benefit of each diagnostic and therapeutic modality requires an estimation of: 1) the likelihood of the diagnosis being considered, 2) the potential outcome of such a diagnosis in the presence or absence of treatment, and 3) the risk of side effects or complications from the diagnostic and therapeutic options, all in the context of patient-specific factors that influence these risks.

**Figures 4 and 5** illustrate a pragmatic systematic approach to the evaluation and management of patients with myocardial injury; however, the authors acknowledge that diagnostic certainty is not always possible.

**Interpreting Serial Troponin Values**

Serial cTn testing to determine whether there is a rise and/or fall in cTn concentrations is required to differentiate between acute and chronic cTn elevation. A non-ischemic ECG and stable pattern of cTn elevation are most consistent with chronic myocardial injury (**Fig. 4**). Dynamic cTn elevation is consistent with acute myocardial injury. The UDMI suggests using a
20% change in cTn to differentiate a stable versus a dynamic cTn pattern, but also recognizes that the optimal change criteria requires individualization based on timing of presentation, absolute cTn concentration and the results of prior testing if available, cTn assay characteristics, and pre-test probability of an acute versus chronic insult. For example, a relative change of 20% in an individual with low cTn concentrations shows poor specificity and positive predictive value for acute MI versus a similar change at higher concentrations. Thus, some experts have proposed using a 50% change near the 99th percentile and a 20% change when the baseline value is more substantially elevated to define a significant cTn change. Furthermore, it may be more efficacious to use absolute changes as opposed to relative changes in cTn to delineate acute from chronic myocardial injury, particularly with high sensitivity cTn assays and when absolute cTn values are low.

Assigning Diagnoses in the “Grey Zones” Between Type 1 MI, Type 2 MI, and Acute Non-Ischemic Myocardial Injury

We believe that in the absence of a clear alternative cause, the initial working diagnosis for most patients with evidence of acute myocardial injury and signs and symptoms consistent with ischemia (e.g., typical chest pain) should be type 1 MI, and should prompt management according to established guidelines for type 1 MI (Fig. 4 and 5). When subsequent evaluation fails to confirm coronary atherothrombosis, further consideration of alternative causes of acute non-ischemic myocardial injury (e.g., myocarditis, pulmonary embolism) or type 2 MI (e.g., supply/demand mismatch, spasm, coronary dissection) is necessary. Importantly, many patients with type 1 MI will have tachycardia, hypertension, and even anemia, and clinicians must be cautious not to over-diagnose type 2 MI in patients with modest supply/demand mismatch; such over diagnosis can lead to delay or withholding of appropriate treatments for type 1 MI. On the
other hand, when type 1 MI is not the most likely cause of myocardial injury, caution must be applied in using diagnostic and treatment strategies with potential for iatrogenic harm. Diagnostic and treatment strategies should be based on a careful assessment of ischemic signs and symptoms, the presence or absence of diagnoses likely to cause ischemic versus non-ischemic myocardial injury, the pre-test probability of type 1 MI, the risk of diagnostic testing modalities (e.g., contrast nephropathy), risk of treatment modalities (e.g., bleeding), and expected outcomes with or without treatment (Fig. 4 and 5).

When acute myocardial injury occurs in the context of another acute illness or surgical procedure, type 2 MI and non-ischemic myocardial injury are more likely than type 1 MI, although it should be recognized that plaque rupture events can be triggered by acute infectious illness or precipitated by perioperative stressors. To distinguish between MI and acute non-ischemic myocardial injury, the first step involves establishing whether there is evidence of myocardial ischemia. Presence or absence of ischemic symptoms can aid in determining ischemia but are not definitive and can be particularly difficult among individuals who are sedated, obtunded, or in the perioperative state. In these cases, ECG surveillance and echocardiography may provide supportive evidence. It is also important to determine if there has been significant myocardial oxygen supply/demand mismatch (e.g., sustained tachycardia, hypoxia, hypotension, severe anemia, coronary spasm), an essential feature in the diagnosis of type 2 MI. In the absence of clear evidence of ischemia and supply/demand mismatch, we favor assigning the diagnosis of acute non-ischemic myocardial injury. The result of this approach is that the diagnoses of type 1 and type 2 MI will be relatively “clean” with higher specificity for the underlying pathophysiological process. The category of non-ischemic myocardial injury will be more diverse, but we anticipate that research will lead to deeper phenotyping to sub-classify...
these individuals more effectively, based on a greater understanding of pathophysiology (see Future Directions). Importantly, as additional data becomes available over the patient’s clinical course, the working diagnosis that best explains the etiology of myocardial injury may also change, and practitioners should continually re-evaluate the diagnostic category and treatment approach as new patient data arises.

*Challenging Clinical Scenarios*

Despite appropriate use of multiple diagnostic tools, the etiology and classification of several common clinical scenarios remain controversial. For example, evidence of myocardial injury (cTn that exceeds the 99th percentile) is ubiquitous among patients presenting with acute decompensated heart failure.\(^{69,70}\) Type 1 MI is a widely recognized precipitant of acute decompensated heart failure; however, multiple mechanisms causal of type 2 MI and non-ischemic myocardial injury in heart failure have been identified, including increased transmural pressure, small-vessel coronary obstruction, endothelial dysfunction, anemia, hypotension, wall stretch resulting in myocyte apoptosis and autophagy, direct myocyte inflammatory, or neurohormonal toxicity.\(^ {71,72}\) Stress cardiomyopathy (also called Takotsubo cardiomyopathy) is a syndrome that includes transient regional systolic dysfunction of the left ventricle, but in the absence of evidence of ischemia. The majority of stress cardiomyopathy cases are thought to be secondary to direct myocardial catecholamine toxicity;\(^ {73}\) therefore, they should be categorized as acute non-ischemic myocardial injury. A minority of cases may be secondary to microvascular dysfunction, coronary artery spasm,\(^ {74}\) or an extra-cardiac stressor that results in a myocardial oxygen supply/demand mismatch; when sufficient evidence exists for these causes of stress cardiomyopathy, categorization as type 2 MI is appropriate. Sepsis is also frequently accompanied by elevated cTn and is associated with increased incidence of adverse outcomes.\(^ {75}\)
Sepsis is associated with multiple categories of myocardial injury, including inflammation as a driver of plaque disruption and resultant atherothrombosis (type 1 MI), inflammation as a cause of direct myocyte toxicity (non-ischemic myocardial injury), and septic shock as a precipitant of tachycardia, hypoperfusion and hypoxemia (type 2 MI). Like sepsis, the post-operative state (from non-cardiac procedures) is also accompanied by systemic inflammation and all classes of myocardial injury, with most studies showing a predominance of type 2 MI or non-ischemic myocardial injury. Post-operative non-ischemic myocardial injury is associated with high short- and long-term mortality.

Consensus in classification will facilitate effective research and design of therapeutic studies for these common entities across different medical facilities. In the absence of evidence for type 1 MI, we propose the default position of acute non-ischemic myocardial injury for patients presenting with evidence of elevated cTn with a dynamic pattern and acute decompensated heart failure, sepsis, or post-operative state from a non-cardiac procedure, and to reserve the designation of type 2 MI for those patients with acute myocardial injury and clear evidence of ischemia or notable extra-cardiac supply/demand mismatch (e.g., significant tachycardia, hypertension, hypotension, hypoxemia or anemia) or acute non-atherothrombotic coronary obstruction (e.g., dissection, embolization).

Treatment

Therapeutic strategies are well established for type 1 MI; however, no compelling data exist for treatment of other myocardial injury categories. Thus, recommendations for the treatment of non-type 1 MI categories are based on the underlying diagnosis resulting in type 2 MI or non-ischemic myocardial injury. Patients who have a clear rise and/or fall in cTn on serial testing and evidence of modest myocardial oxygen supply/demand imbalance require careful
consideration of the pre-test probability of type 1 MI, risks of diagnostic tests to guide the initial investigation, and risks of giving or withholding type 1 MI treatment (Fig. 4 and 5). If the likelihood of type 1 MI is high (typical symptoms, dynamic ECG changes, or very high cTn concentration), and the risks of treatment low, then anti-thrombotic therapies and invasive coronary imaging are prudent (Fig. 5). If a culprit coronary lesion is identified, angiographic features or additional data from adjuvant intra-vascular imaging may identify coronary thrombosis, establishing the diagnosis of type 1 MI, or non-thrombotic coronary pathology (dissection, embolism, spasm), establishing the diagnosis of type 2 MI. If no culprit coronary lesion is identified, the presence of a clear extra-cardiac supply/demand mismatch would provide support for a diagnosis of type 2 MI, while absence of such pathology should prompt a re-evaluation for the presence of ischemia, and if ischemia is not confirmed, consideration of acute non-ischemic myocardial injury (Fig. 4). However, the imperfect sensitivity of invasive angiography for identifying a culprit thrombus should be taken into account.

In patients with a low pre-test probability of type 1 MI (atypical [or no] symptoms, normal ECG) or a high risk of iatrogenic complications, a more conservative approach is prudent, with consideration of deferral of anti-thrombotic therapy and invasive angiography (Fig. 5). Therapeutic and diagnostic decisions should be continually re-evaluated as additional data become available for an individual patient. Echocardiography can provide relevant and safe information that can inform diagnosis and risk assessment. The absence of significant atherosclerosis on CT coronary angiography virtually eliminates type 1 MI from the differential diagnosis, which may have significant therapeutic implications. Patients with intermediate pre-test probabilities, and those at higher risk of treatment complications (Fig. 5), are more
challenging, and will require an individualized approach with careful clinical assessment and judgement.

For patients with type 2 MI, treatment of the primary cause of supply/demand mismatch is paramount. In the absence of contraindications (e.g., bradycardia, hypotension, acute heart failure), early judicious use of beta blockers to control high myocardial demand should be considered while additional diagnostic and treatment strategies are ongoing or awaiting implementation. Furthermore, we recommend consideration of establishing the presence or absence of coronary artery disease and structural cardiac disease, if not already known, with functional or anatomic studies, provided this is appropriate in the context of the patient’s non-cardiac conditions and goals of care. This recommendation is not based on trial data, but rather, on the observation that type 2 MI may reflect the presence of flow (supply) limiting CAD when demand is high. Similarly, the threshold for type 2 MI will be lower among individuals with severe left ventricular hypertrophy as is seen in aortic stenosis, hypertrophic cardiomyopathy, and other conditions. This evaluation can occur electively after the acute condition leading to supply/demand mismatch is controlled.

Long-term treatment strategies for type 2 MI in the absence of CAD lack trial data or guidelines. Data from the SWEDEHEART registry were used to identify 9136 patients with a discharge diagnosis of acute MI who did not have a stenosis of \( \geq 50\% \) on coronary angiography and survived the first 30 days after discharge—criteria consistent with MINOCA. While MINOCA may include type 1 MI patients, the majority of MINOCA patients are classified as type 2 MI via UDMI criteria. Therefore, these data may also provide some insight into therapies that may be beneficial in Type 2 MI. In this observational study, discharge with an ACEI/ARB and statin were both associated with a lower incidence of MACE over a mean follow-up of 4.1
years. Dual anti-platelet therapy was associated with a numerically lower risk of MACE and a trend toward more bleeding. Others have observed reduced odds of death at 2 years in patients with type 2 MI who used beta blockers versus those who did not. Collectively, these data are weakly supportive of a role for ACEI/ARB, statins, and beta blockers in patients with type 2 MI, but are limited by confounding inherent to observational study design, lack of focus specifically on type 2 MI, and a lack of knowledge of other indications (unrelated to incident MI) present in these patients (i.e., indication bias). These data also highlight the potential bleeding risk of dual anti-platelet therapy in this patient population.

Non-ischemic myocardial injury includes a heterogeneous group of diagnoses that result in acute or chronic elevations of cTn; as such, treatment is reasonably based on the specific underlying causal diagnosis. Given the observed association between non-ischemic myocardial injury and structural heart disease, we advocate for consideration of cardiac imaging (e.g., echocardiography, cardiac MRI) to evaluate for structural heart disease (e.g., cardiomyopathy) when the underlying condition resulting in non-ischemic myocardial injury is unknown. All patients, including those with evidence of myocardial injury but without known cardiovascular disease (CVD), should be evaluated for primary CVD (e.g., atherosclerosis, heart failure) prevention consistent with current guidelines.

**Future Directions**

*Need for Epidemiological Studies*

The Fourth UDMI provides an enhanced taxonomy for classification of myocardial injury (type 1 MI, type 2 MI, non-ischemic myocardial injury) that will facilitate study of these common diagnoses with a more structured approach than previously possible. The epidemiology of Type 2 MI and non-ischemic myocardial injury remains uncertain, and better understanding is needed...
to advance mechanistic insights as well as the prediction, prevention, and treatment of these conditions. There are substantial gaps in knowledge regarding the relationship between risk factors and the different types of acute MI and other causes of myocardial injury. Such knowledge may not only allow for development of more accurate cardiovascular risk prediction models, but also more judicious application of current preventive therapies, e.g., more aggressive anti-thrombotic therapy for those at greatest risk for type 1 (atherothrombotic) versus type 2 (supply/demand ischemia) MI. Moreover, evaluation of individual sub-types of acute MI will increase the opportunity for identifying new risk factors that may themselves become therapeutic targets. The implications of better phenotyping are equally important for therapeutic trials. For example, candidate anti-thrombotic therapies would only be expected to benefit participants with MI from an atherothrombotic etiology (type 1 MI), whereas participants with MI of non-thrombotic etiology (type 2 MI) could be exposed to unnecessary harm (e.g., bleeding) without potential for clinical benefit. Indeed, it is possible that inclusion of a large proportion of patients with type 2 MI or non-ischemic injury may lead to false null conclusions of clinical trials testing novel therapies for type 1 MI.

**Coding For Type 2 MI and Acute Non-Ischemic Myocardial Injury**

In 2017, an International Classification of Disease (ICD) code was introduced for type 2 MI (ICD-10 code I21.A1). Although type 2 MI may present with or without ST-segment elevation, the ICD-10 code for type 2 MI does not include (or allow for) this distinction. Prior to the availability of an ICD code for type 2 MI, patients meeting criteria for type 2 MI were much less likely to be coded as an MI than patients meeting criteria for type 1 MI. In one study, among the 180 subjects adjudicated as an acute MI but not coded as acute MI by the treating physician, 81% were adjudicated as type 2 MI compared with 19% type 1 MI. This is in contrast to the
patients who received a diagnostic code for acute MI: 85% were adjudicated as type 1 MI and 15% were adjudicated as type 2 MI. Using UDMI Fourth edition taxonomy, independent adjudication of all patients coded as a type 2 MI at a large academic center (633 patients) classified 57% as type 2 MI, 42% as myocardial injury, 1% as type 1 MI, 0.5% as unstable angina. Miscoding myocardial injury as MI will impede study of both MI and other types of myocardial injury and may have financial ramifications, as such events would be included as MI under readmission penalties and/or value-based programs. Although there is no specific ICD code designation for non-ischemic myocardial injury, some have advocated for coding this diagnosis as ICD-10 R79.89 (abnormal blood chemistry) to reflect the abnormal elevation in cTn. However, we do not agree with this nonspecific approach, and advocate for appropriate ICD-10 codes to be developed for acute and chronic myocardial injury. Similarly, ICD-10 S26 codes denote “injury of heart,” however, these codes are specific for myocardial injury resulting from direct physical trauma (e.g., contusions or lacerations) and should not be used for other forms of non-ischemic myocardial injury.

**Novel Diagnostic Approaches**

Additional investigative approaches are needed to enable early diagnosis of MI subtypes and to guide appropriate and timely treatment of patients with myocardial injury according to underlying etiology. DEMAND-MI is an ongoing prospective observational cohort study that aims to establish the prevalence of obstructive CAD in participants with type 2 MI (ClinicalTrials.gov NCT03338504). Participants undergo detailed phenotyping with invasive coronary angiography, OCT and fractional flow reserve of coronary lesions, or CTA, if not amenable to invasive assessment. All participants also undergo cardiac MRI with late...
gadolinium enhancement to characterize the presence, pattern, and quantity of acute and/or chronic myocardial injury.

Although the principal distinction between type 1 and type 2 MI is the presence of a disrupted plaque with associated thrombus, prompt identification of a culprit lesion with thrombus before deciding therapy is difficult; hence, biomarkers of thrombus formation could be helpful in guiding clinical care. Discovery metabonomics has identified metabolic changes at the time of acute MI that are distinctly associated with thrombotic MI (type 1) compared with type 2 MI, acute non-ischemic myocardial injury, or stable CAD. Individual biomarkers or panels of biomarkers await validation. Research demonstrating that up to 79% of plaque disruptions heal without coronary thrombosis and resultant acute MI has spawned interest in identifying determinants of pathological thrombosis at the time of plaque rupture. Preliminary studies suggest oxidized phospholipids (OxPLs) may be one such determinant. When bound to plasminogen (PLG), OxPL facilitates fibrinolysis, and levels of OxPL-PLG are lower among type 1 (thrombotic) MI versus type 2 (non-thrombotic) MI patients. Using the radiotracer 18F-fluoride, positron emission tomography (PET) imaging may identify ruptured coronary plaques, making PET one of the few imaging modalities capable of identifying acute type 1 MI. Additional study is needed to determine if these or other biomarkers allow for differentiation of type 1 MI from type 2 MI in the appropriate clinical setting.

New Therapeutic Approaches

The utility of currently available primary and secondary preventive strategies, effective in type 1 MI and stable CAD, have not been adequately evaluated for type 2 MI or non-ischemic myocardial injury. The appropriateness of coronary investigation in myocardial injury and Type 2 MI (ACT-2) is being studied in an ongoing randomized control trial of early coronary
angiography versus conservative management in participants with criteria consistent with type 2 MI, acute or chronic non-ischemic myocardial injury.97

Given the reduction of myocardial demand with beta blocker therapy, this intervention may be particularly applicable to treatment and prevention of type 2 MI, and warrants additional study. New and specific treatments for type 2 MI and non-ischemic myocardial injury will require an understanding of the heterogeneous group of conditions that leads to these two diagnoses. Therapeutics for type 2 MI or non-ischemic myocardial injury, independent of the underlying precipitating diagnosis, require a greater understanding of whether and how such myocardial injury results in adverse clinical outcomes independent of the precipitating diagnoses.

Conclusion

Myocardial injury can result from a wide variety of ischemic and non-ischemic mechanisms. Type 2 MI and non-ischemic myocardial injury encompass a heterogeneous group of mechanisms that may warrant different therapeutic approaches. We provide a framework for diagnosis and management of patients with acute myocardial injury, but encourage additional research to define the validity of this and any future approaches for this common clinical presentation.

Acknowledgments

The authors acknowledge Allison E. Smith at the University of Louisville for her editing assistance.
Sources of Funding

None

Disclosures

Dr. DeFilippis has grant support from the National Institutes of Health, AstraZeneca, and has received consulting income from Radiometer.

Dr. Chapman has had research support and speaker fees from Abbott Diagnostics and Siemens Healthineers.

Dr. Mills has received consulting income from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and Singulex, and the University of Edinburgh has received research grants from Abbott Diagnostics and Siemens Healthineers.

Dr. Chapman and Dr. Mills are supported by the British Heart Foundation through personal fellowships (FS/16/75/32533, FS/16/14/32023) and a Research Excellence Award (RE/18/5/34216).

Dr. de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics, and consulting income from Roche Diagnostics, Abbott Diagnostics, Siemens Health Care Diagnostics, Ortho Clinical Diagnostics, Quidel Cardiovascular, Radiometer, and Jannsen.

Dr. Zadeh reports no conflict of interest.

Dr. Newby has received research grant support from Boehringer-Ingelheim, GlaxoSmithKline, and Amylin-BMS, and consulting honoraria from Ortho-Clinical Diagnostics, Roche Diagnostics, Metanomics, and BioKier.
Dr. Morrow reports research grants from Abbott Laboratories, Amgen, AstraZeneca, BRAHMS, Eisai, GSK, Medicines Co, Merck, Novartis, Pfizer, Roche, Takeda, and consulting fees from Abbott Laboratories, Aralez, AstraZeneca, Bayer, InCardia, Roche.

References

1. Pitts SR, Niska RW, Xu J, Burt CW. National hospital ambulatory medical care survey: 2006 emergency department summary. *Natl Health Stat Report*. 2008:1-38

2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C, Stroke Statistics S. Heart disease and stroke statistics--2014 update: A report from the American Heart Association. *Circulation*. 2014;129:e28-e292

3. Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Diamond GA, Fesmire FM, Geraci SA, Gersh BJ, Larsen GC, Kaul S, McKay CR, Philippides GJ, Weintraub WS. Accf 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: A report of the American College of Cardiology foundation task force on clinical expert consensus documents. *Journal of the American College of Cardiology*. 2012;60:2427-2463

4. Thygesen K, Alpert JS, Chaitman BR, Bax JJ, Morrow DA, White HD, Group ESCS. Fourth universal definition of myocardial infarction (2018). *Circulation*. 2018;138:e618–e651

5. Luepker RV, Duval S, Jacobs DR, Jr., Smith LG, Berger AK. The effect of changing diagnostic algorithms on acute myocardial infarction rates. *Ann Epidemiol*. 2011;21:824-829

6. Reiter M, Twerynewski R, Reichlin T, Haaf P, Peter F, Meissner J, Hochholzer W, Stelzig C, Freese M, Heinisch C, Breidthardt T, Freidank H, winkler K, Campodarve I, Gea J, Mueller C. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. *Eur Heart J*. 2011;32:1379-1389

7. Nicole S, Scalone G, Crea F. Acute myocardial infarction with no obstructive coronary atherosclerosis: Mechanisms and management. *Eur Heart J*. 2015;36:475-481

8. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Hashim I, berry JD, Das SR, Morrow DA, Mcguire DK. Association of troponin t detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. *JAMA*. 2010;304:2503-2512

9. Sandoval Y, Smith SW, Sexten A, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver BE, Hu Y, Jacoby K, Johnson BK, Love SA, Moore JC, Schulz K, Scott NL,
Apple FS. Type 1 and 2 myocardial infarction and myocardial injury: Clinical transition to high-sensitivity cardiac troponin i. *Am J Med*. 2017;130:1431-1439

10. Meigher S, Thode HC, Peacock WF, Bock JL, Gruber L, Singer AJ. Causes of elevated cardiac troponins in the emergency department and their associated mortality. *Acad Emerg Med*. 2016;23:1267-1273

11. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbucher D, Sabti Z, Puelacher C, Rubini Gimenez M, Kozhuharov N, Strebel I, Sazgery L, Schneider D, Jann J, du Fay de Lavallaz J, Miro O, Martin-Sanchez FJ, Morawiec B, Kawecki D, Muzyk P, Keller DI, Geigy N, Osswald S, Reichlin T, Mueller C, Investigators A. Effect of definition on incidence and prognosis of type 2 myocardial infarction. *Journal of the American College of Cardiology*. 2017;70:1558-1568

12. Cediel G, Gonzalez-Del-Hoyo M, Carrasquer A, Sanchez R, Boque C, Bardaji A. Outcomes with type 2 myocardial infarction compared with non-ischaemic myocardial injury. *Heart*. 2017;103:616-622

13. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Renne T, Qaderi V, Teltrop E, Kramer S, Quantius L, Zeller T, Karakas M, Blankenberg S, Westermann D. Discrimination of patients with type 2 myocardial infarction. *Eur Heart J*. 2017;38:3514-3520

14. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: Frequency and features of type 2 myocardial infarction. *Am J Med*. 2013;126:789-797

15. Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, Gerke O, Hallas J, Thygesen K, Mickley H. Mortality rate in type 2 myocardial infarction: Observations from an unselected hospital cohort. *Am J Med*. 2014;127:295-302

16. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N, Hosbond S, Diederichsen AC, Thygesen K, Mickley H. Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and nonelevated troponins, *Am J Med*. 2016;129:446 e445-446 e421

17. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Hosbond S, Jangaard N, Diederichsen AC, Thygesen K, Mickley H. Prognostic impact of myocardial injury related to various cardiac and noncardiac conditions. *Am J Med*. 2016;129:506-514 e501

18. Javed U, Aftab W, Ambrose JA, Wessel RJ, Mouanoutoua M, Huang G, Barua RS, Weilert M, Sy F, Thatai D. Frequency of elevated troponin i and diagnosis of acute myocardial infarction. *Am J Cardiol*. 2009;104:9-13

19. Melberg T, Burman R, Dickstein K. The impact of the 2007 esc-acc-aha-whf universal definition on the incidence and classification of acute myocardial infarction: A retrospective cohort study. *Int J Cardiol*. 2010;139:228-233

20. Gonzalez MA, Eilen DJ, Marzouq RA, Porterfield CP, Hazarika S, Nasir S, Patel AA, Gonzalez Kde J, Burris MB, Prieto-Gonzalez M, Rose JD, Cascio WE, Multidisciplinary Atherosclerosis Prevention P. The universal classification is an independent predictor of long-term outcomes in acute myocardial infarction. *Cardiovasc Revasc Med*. 2011;12:35-40

21. Stein GY, Herscovici G, Korenfeld R, Matetzky S, Gottlieb S, Alon D, Gevrielov-Yusim N, Iakobishvili Z, Fuchs S. Type-II myocardial infarction--patient characteristics, management and outcomes. *PLoS One*. 2014;9:e84285
22. El-Haddad H RE, Swett K, Wells GL. Prognostic implications of type 2 myocardial infarctions. *World Journal of Cardiovascular Diseases*. 2012;2:237-241
23. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, Anand A, Fersia O, Joshi NV, Walker S, Jaffe AS, Fox KA, Newby DE, Mills NL. Sensitive troponin assay and the classification of myocardial infarction. *Am J Med*. 2015;128:493-501 e493
24. Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson P, McAllister DA, Strachan F, Newby DE, Mills NL. Long term outcomes in patients with type 2 myocardial infarction and myocardial injury. *Circulation*. 2018;137:1236-1245
25. Smilowitz NR, Subramanyam P, Gianos E, Reynolds HR, Shah B, Sedlis SP. Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction. *Coron Artery Dis*. 2018;29:46-52
26. Lambrecht S, Sarkisian L, Saaby L, Poulsen TS, Gerke O, Hosbond S, Diederichsen ACP, Thygesen K, Mickley H. Different causes of death in patients with myocardial infarction type 1, type 2, and myocardial injury. *Am J Med*. 2018;131:548-554
27. Baron T, Hambraeus K, Sundstrom J, Erlinge D, Jernberg T, Lindahl B, group T-As. Type 2 myocardial infarction in clinical practice. *Heart*. 2015;101:101-106
28. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: An application of the classification system from the universal definition of myocardial infarction. *Circulation*. 2009;119:2758-2764
29. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: Observations from the tritontimi 38 trial (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). *Circulation*. 2012;125:577-583
30. Wong P, Murray S, Ramsewak A, Robinson A, van Heyningen C, Rodrigues E. Raised cardiac troponin t levels in patients without acute coronary syndrome. *Postgrad Med J*. 2007;83:200-205
31. Wong PS, Jones JD, Ashrafi R, Khanzada O, Wickramarachchi U, Keen TH, Robinson DR. Early and late mortality in hospitalised patients with raised cardiac troponin t. *Postgrad Med J*. 2012;88:437-442
32. Gard A, Lindahl B, Batra G, Hadziosmanovic N, Hjort M, Szummer KE, Baron T. Interphysician agreement on subclassification of myocardial infarction. *Heart*. 2018;104:1284-1291
33. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KA, Newby DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: Prospective cohort study. *BMJ*. 2015;350:g7873
34. Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT, Ornato JP, Barron HV, Kiefe CI. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. *JAMA*. 2000;283:3223-3229

35. Mackay MH, Ratner PA, Johnson JL, Humphries KH, Buller CE. Gender differences in symptoms of myocardial ischaemia. *Eur Heart J*. 2011;32:3107-3114

36. Culic V, Eterovic D, Miric D, Silic N. Symptom presentation of acute myocardial infarction: Influence of sex, age, and risk factors. *Am Heart J*. 2002;144:1012-1017

37. Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in myocardial infarction secondary prevention: The national health and nutrition examination surveys (NHANES), 1999-2012. *J Am Heart Assoc*. 2015;4: e001709

38. Arnold SV, Lipska KJ, Li Y, McGuire DK, Goyal A, Spertus JA, Kosiborod M. Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction. *Am Heart J*. 2014;168:466-470 e461

39. Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, Sadiq I, Kasper R, Rushton-Mellor SK, Anderson FA, Investigators G. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the global registry of acute coronary events (GRACE). *Am J Cardiol*. 2002;90:358-363

40. Zaman MJ, Stirling S, Shepstone L, Ryding A, Flather M, Bachmann M, Myint PK. The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: A cohort study of the myocardial ischaemia national audit project (MINAP). *Eur Heart J*. 2014;35:1551-1558

41. Pride YB, Piccirillo BJ, Gibson CM. Prevalence, consequences, and implications for clinical trials of unrecognized myocardial infarction. *Am J Cardiol*. 2013;111:914-918

42. Zhang ZM, Rautaharju PM, Prineas RJ, Rodriguez CJ, Loehr L, Rosamond WD, Kitzman D, Couper D, Soliman EZ. Race and sex differences in the incidence and prognostic significance of silent myocardial infarction in the atherosclerosis risk in communities (ARIC) study. *Circulation*. 2016;133:2141-2148

43. Larson DM, Menssen KM, Sharkey SW, Duval S, Schwartz RS, Harris J, Meland JT, Unger BT, Henry TD. "False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. *JAMA*. 2007;298:2754-2760

44. Sandoval Y, Thordsen SE, Smith SW, Schulz KM, Murakami MM, Pearce LA, Apple FS. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. *Eur Heart J Acute Cardiovasc Care*. 2014;3:317-325

45. Amraotkar AR, Ghafghazi S, Trainor PJ, Hargis CW, Irfan AB, Rai SN, Bhatnagar A, DeFilippis AP. Presence of multiple coronary angiographic characteristics for the diagnosis of acute coronary thrombus. *Cardiol J*. 2017;24:25-34

46. Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenoses: Histopathologic correlations. *Circulation*. 1982;66:316-320

47. den Heijer P, Foley DP, Escaned J, Hillege HL, van Dijk RB, Serruys PW, Lie KL. Angioscopic versus angiographic detection of intimal dissection and intracoronary thrombus. *Journal of the American College of Cardiology*. 1994;24:649-654
48. Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T. Assessment of culprit lesion morphology in acute myocardial infarction: Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. *Journal of the American College of Cardiology*. 2007;50:933-939

49. Arbab-Zadeh A, Fuster V. The myth of the "vulnerable plaque": Transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. *Journal of the American College of Cardiology*. 2015;65:846-855

50. Gerber BL. MRI versus CT for the detection of coronary artery disease: Current state and future promises. *Curr Cardiol Rep*. 2007;9:72-78

51. Leber AW, Becker A, Knez A, von Ziegler F, Sirol M, Nikolaou K, Ohnesorge B, Fayad ZA, Becker CR, Reiser M, Steinbeck G, Boekstegers P. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: A comparative study using intravascular ultrasound. *Journal of the American College of Cardiology*. 2006;47:672-677

52. Ozaki Y, Okumura M, Ismail TF, Motoyama S, Naruse H, Hattori K, Kawai H, Sarai M, Takagi Y, Ishii J, Anno H, Virmani R, Serruys PW, Narula J. Coronary CT angiographic characteristics of culprit lesions in acute coronary syndromes not related to plaque rupture as defined by optical coherence tomography and angioscopy. *Eur Heart J*. 2011;32:2814-2823

53. Obaid DR, Calvert PA, Brown A, Gopalan D, West NEJ, Rudd JHF, Bennett MR. Coronary CT angiography features of ruptured and high-risk atherosclerotic plaques: Correlation with intra-vascular ultrasound. *J Cardiovasc Comput Tomogr*. 2017;11:455-461

54. Motoyama S, Ito H, Sarai M, Nagahara Y, Miyajima K, Matsumoto R, Doi Y, Kataoka Y, Takahashi H, Ozaki Y, Toyama H, Katada K. Ultra-high-resolution computed tomography angiography for assessment of coronary artery stenosis. *Circ J*. 2018;82:1844-1851

55. Maffei E, Seitz S, Guaricci AI, Cademartiri F. Chest pain: Coronary CT in the ER. *Br J Radiol*. 2016;89:20150954

56. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, Ganesh SK, Gulati R, Lindsay ME, Mieres JH, Naderi S, Shah S, Thaler DE, Tweet MS, Wood MJ, American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, Council on Cardiac Rehabilitation, Council on Cardiovascular Radiology, Council on Cardiovascular Imaging. Spontaneous coronary artery dissection: Current state of the science: A scientific statement from the American Heart Association. *Circulation*. 2018;137:e523-e557

57. Tweet MS, Gulati R, Williamson EE, Vrtiska TJ, Hayes SN. Multimodality imaging for spontaneous coronary artery dissection in women. *JACC Cardiovasc Imaging*. 2016;9:436-450

58. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, Pizzi MN, Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P, Fernandez-Golfín C, Rincon LM, Graner FP, de Graaf MA, Fiechter M, Stehli J, Gaemperli O, Reyes E, Nkomo S, Maki M, Lorenzoni V, Turchetti G, Carpeggiani C, Marinelli M, Pizzoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ,
Zamorano JL, Kaufmann PA, Underwood SR, Knuuti J, Investigators ES. Detection of significant coronary artery disease by noninvasive anatomical and functional imaging. *Circ Cardiovasc Imaging*. 2015;8:e002179

59. Rajiah P, Desai MY, Kwon D, Flamm SD. MR imaging of myocardial infarction. *Radiographics*. 2013;33:1383-1412

60. Sakuma H. Magnetic resonance imaging for ischemic heart disease. *J Magn Reson Imaging*. 2007;26:3-13

61. Dweck MR, Puntman V, Vesey AT, Fayad ZA, Nagel E. MR imaging of coronary arteries and plaques. *JACC Cardiovasc Imaging*. 2016;9:306-316

62. Dastidar AG, Rodrigues JC, Ahmed N, Baritussio A, Bucciarelli-Ducci C. The role of cardiac MRI in patients with troponin-positive chest pain and unobstructed coronary arteries. *Curr Cardiovasc Imaging Rep*. 2015;8:28

63. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. *Journal of the American College of Cardiology*. 2018;72:3158-3176

64. Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J, Bio-Markers ITFoCAoC. Cardiac troponin assays: Guide to understanding analytical characteristics and their impact on clinical care. *Clin Chem*. 2017;63:73-81

65. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, Huber K, Plebani M, Biasucci LM, Tubaro M, Collinson P, Venge P, Hasin Y, Galvani M, Koenig W, Hamm C, Alpert JS, Katus H, Jaffe AS, Study Group on Biomarkers in Cardiology of ESCWGoACC. How to use high-sensitivity cardiac troponins in acute cardiac care. *Eur Heart J*. 2012;33:2252-2257

66. Mueller C, Giannitsis E, Christ M, Ordonez-Llanos J, deFilippi C, McCord J, Body R, Panteghini M, Jernberg T, Plebani M, Verschuren F, French J, Christenson R, Weiser S, Bendig G, Dilba P, Lindahl B, Investigators T-A. Multicenter evaluation of a 0-hour/1-hour algorithm in the diagnosis of myocardial infarction with high-sensitivity cardiac troponin t. *Ann Emerg Med*. 2016;68:76-87 e74

67. Reichlin T, Irfan A, Twerenbold R, Reiter M, Hochholzer W, Burkhalter H, Bassetti S, Steuer S, Winkler K, Peter F, Meissner J, Haaf P, Potocki M, Drexler B, Osswald S, Mueller C. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. *Circulation*. 2011;124:136-145

68. Mushar DM, Abers MS, Corrales-Medina VF. Acute infection and myocardial infarction. *N Engl J Med*. 2019;380:171-176

69. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdes M, Januzzi JL. Soluble st2, high-sensitivity troponin t- and n-terminal pro-b-type natriuretic peptide: Complementary role for risk stratification in acutely decompensated heart failure. *Eur J Heart Fail*. 2011;13:718-725

70. Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin i predict outcome in patients with decompensated heart failure. *Eur J Heart Fail*. 2011;13:37-42

71. Januzzi JL, Jr., Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: On behalf of the third universal definition of myocardial infarction global task force: Heart failure section. *Eur Heart J*. 2012;33:2265-2271
72. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. *Journal of the American College of Cardiology*. 2010;56:1071-1078

73. Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Champion HC. Neurohumoral features of myocardial stunning due to sudden emotional stress. *N Engl J Med*. 2005;352:539-548

74. Galiuto L, De Caterina AR, Porfidia A, Paraggio L, Barchetta S, Locorotondo G, Rebuzzi AG, Crea F. Reversible coronary microvascular dysfunction: A common pathogenetic mechanism in apical ballooning or tako-tsubo syndrome. *Eur Heart J*. 2010;31:1319-1327

75. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: Incidence and clinical significance. *Chest*. 2004;125:1877-1884

76. Thygesen K, Alpert JS, Jaffe AS, White HD. Diagnostic application of the universal definition of myocardial infarction in the intensive care unit. *Curr Opin Crit Care*. 2008;14:543-548

77. Crea F, Libby P. Acute coronary syndromes: The way forward from mechanisms to precision treatment. *Circulation*. 2017;136:1155-1166

78. Drosatos K, Lymeropoulos A, Kennel PJ, Pollak N, Schulze PC, Goldberg JJ. Pathophysiology of sepsis-related cardiac dysfunction: Driven by inflammation, energy mismanagement, or both? *Curr Heart Fail Rep*. 2015;12:130-140

79. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. *Circulation*. 2009;119:2936-2944

80. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study I, Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccard BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada M, Thomas S, Rodseth RN, Pearse RM, Thabane L, McQueen MJ, VanHelder T, Bhandari M, Bosch J, Kurz A, Polanczyk C, Madara G, Nagele P, Le Manach Y, Leuwer M, Yusuf S. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. *JAMA*. 2012;307:2295-2304

81. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, Leslie K, Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum A, Lanthier L, Hu W, Yusuf S, Investigators P. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: A cohort study. *Ann Intern Med*. 2011;154:523-528

82. Puelacher C, Lurati Buse G, Seeberger D, Sazgary L, Marbot S, Lampart A, Espinola J, Kindler C, Hammerer A, Seeberger E, Strebel I, Wildi K, Twerenbold R, du Fay de Lavaissiere J, Steinle L, Gurke L, Breidhardt T, Rentsch K, Buser A, Gualandro DM, Osswald S, Mueller C, Investigators B-P. Perioperative myocardial injury after noncardiac surgery: Incidence, mortality, and characterization. *Circulation*. 2018;137:1221-1232

83. Lindahl B, Baron T, Erlinge D, Hadziosmanovic N, Nordenskjold A, Gard A, Jernberg T. Medical therapy for secondary prevention and long-term outcome in patients with
myocardial infarction with nonobstructive coronary artery disease. *Circulation*. 2017;135:1481-1489

84. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y, American Heart Association Council on E, Prevention, American Heart Association Council on Clinical C, American Heart Association Council on Cardiovascular N, American Heart Association Council on High Blood Pressure R, Quality of C, Outcomes Research Interdisciplinary Working G, Functional G, Translational Biology Interdisciplinary Working G. Prevention of heart failure: A scientific statement from the American Heart Association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing, and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. *Circulation*. 2008;117:2544-2565

85. Grundy SM, Stone NJ, Bailey AL, Beam C, Birchter KK, Blumenthal RS, Braun LT, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: Executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Journal of the American College of Cardiology*. 2019;139:e1046-e1081

86. DeFilippis AP, Nasir K, Blaha MJ. Myocardial infarction as a clinical endpoint in research—what are we really talking about? *Circulation Research*. 2019;124:1701-1703

87. Diaz-Garzon J, Sandoval Y, Smith SW, Love S, Schulz K, Thordsen SE, Johnson BK, Driver B, Jacoby K, Carlson MD, Dodd KW, Moore J, Scott NL, Bruen CA, Hatch R, Apple FS. Discordance between ICD-coded myocardial infarction and diagnosis according to the universal definition of myocardial infarction. *Clin Chem*. 2017;63:415-419

88. McCarthy C, Murphy S, Cohen JA, Rehman S, Jones-O’Connor M, Olshan DS, Singh A, Vaduganathan M, Januzzi JL, Jr., Wasfy JH. Misclassification of myocardial injury as myocardial infarction: Implications for assessing outcomes in value-based programs. *JAMA Cardiol*. 2019;4:460-464

89. Abhinav Goyal M, MHS, FACC; Tyler J. Gluckman, MD, FACC; Andrew Levy, MD; Debra Mariani; Christine Perez; Geoffrey A. Rose, MD, FACC; Susan Sweeney, MPH; Randall C. Thompson, MD, FACC; Dr. Thad F. Waites, MD, MACC; James E. Tcheng, MD, FACC. Translating the fourth universal definition of myocardial infarction into clinical documentation: Ten pearls for frontline clinicians. *American College of Cardiology Magazine*. Nov 6, 2018;https://www.acc.org/latest-in-cardiology/articles/2018/11/06/12/42/translating-the-fourth-universal-definition-of-myocardial-infarction-into-clinical-documentation-ten-pearls-for-frontline-clinicians

90. DeFilippis AP, Trainor PJ, Hill BG, Amraotkar AR, Rai SN, Hirsch GA, Rouchka EC, Bhatnagar A. Identification of a plasma metabolomic signature of thrombotic myocardial infarction that is distinct from non-thrombotic myocardial infarction and stable coronary artery disease. *PLoS One*. 2017;12:e0175591
91. Trainor PJ, Hill BG, Carlisle SM, Rouchka EC, Rai SN, Bhatnagar A, DeFilippis AP. Systems characterization of differential plasma metabolome perturbations following thrombotic and non-thrombotic myocardial infarction. *J Proteomics*. 2017;160:38-46

92. Trainor PJ, Yampolskiy RV, DeFilippis AP. Wisdom of artificial crowds feature selection in untargeted metabolomics: An application to the development of a blood-based diagnostic test for thrombotic myocardial infarction. *J Biomed Inform*. 2018;81:53-60

93. Leibundgut G, Arai K, Orsoni A, Yin H, Scipione C, Miller ER, Koschinsky ML, Chapman MJ, Witztum JL, Tsimikas S. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. *Journal of the American College of Cardiology*. 2012;59:1426-1437

94. DeFilippis AP, Chernyavskiy I, Amraotkar AR, Trainor PJ, Kothari S, Ismail I, Hargis CW, Korley FK, Leibundgut G, Tsimikas S, Rai SN, Bhatnagar A. Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. *J Thromb Thrombolysis*. 2016;42:61-76

95. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. 18f-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. *Lancet*. 2014;383:705-713

96. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial 18f-sodium fluoride uptake: A novel marker of plaque biology. *Journal of the American College of Cardiology*. 2012;59:1539-1548

97. Kristina Lambrakis JKF, Ian A. Scott, Tom Briffa, David Brieger, Michael E. Farkouh, Harvey White, Anthony (Ming-Yu) Chuang, Kathryn Tiver, Stephen Quinn, Billingsley Kaambwa, Matthew Horsfall, Erin Morton, Derek P Chew. The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (act-2): A randomized trial design. *Am Heart J*. 2019;208:11-20
Figure Legends

Figure 1. Myocardial injury taxonomy

Figure 2. All cause mortality in cohort studies of patients with type 1 myocardial infarction (MI), type 2 MI, or myocardial injury. Size of bubble indicates number of patients in the study (small <1000, medium <3000, large >3000) with color representing diagnosis (type 1 MI = red, type 2 MI = blue, myocardial injury = purple). Label indicates lead author from cohort.

*In most of the depicted studies, the category of ‘myocardial injury’ was aimed at capturing acute non-ischemic myocardial injury.

Figure 3. Peak cardiac troponin concentration among patients with type 1 myocardial infarction (MI), type 2 MI, or non-ischemic myocardial injury. Boxes represent medians and interquartile ranges (IQRs), whiskers display the maximum and minimum values. All units standardized to micrograms per liter with y axis transformed as log10.

*In most of the depicted studies, the category of ‘myocardial injury’ was aimed at capturing acute non-ischemic myocardial injury.

Figure 4. Systematic approach to the evaluation, classification, and treatment of patients presenting with evidence of myocardial injury. Gradation of coloring represents the gradation of assessed probability of myocardial ischemia (orange) and type 1 MI (red), with darker coloring representing higher likelihood.
MI=myocardial infarction, cTN=cardiac troponin, ECG=electrocardiogram, CMR=cardiac magnetic resonance imaging, CAD=coronary artery disease, ASCVD=atherosclerotic cardiovascular disease

**Figure 5. Proposed conceptual paradigm for the evaluation and treatment of patients presenting with symptoms and/or signs of myocardial infarction.** Gradation of coloring represents the gradation of assessed probability of type 1 myocardial infarction (MI) (red) and diagnostic iatrogenic risk (blue), with darker coloring representing higher likelihood. Dotted lines represent how different combinations of different pre-test probabilities of type 1 MI and risk of a diagnostic modality or treatment may impact selection of diagnostic modalities or empiric treatments. For example, patients with a low pre-test probability of type 1 MI and a high risk of bleeding or contrast induced nephropathy should not receive the same diagnostic evaluation and empiric anti-thrombotic treatment as a patient with a high probability of type 1 MI and a low risk for bleeding or contrast induced nephropathy. Decisions on patients not at these extremes are more nuanced.

ECG=electrocardiogram, cTN=cardiac troponin, GI=gastrointestinal, NSAID=nonsteroidal anti-inflammatory drug, PCI=percutaneous coronary intervention
### Table 1. Abbreviated classification of myocardial injury (definitions derived from the Fourth Universal Definition of Acute Myocardial Infarction).

| Classification                  | Definition                                                                                                                                 |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| Acute Myocardial Infarction (MI)| Clinical evidence of acute myocardial injury as evident from detection of a rise and/or fall of cTn values with at least one value above the 99th percentile URL and at least one of the following symptoms of myocardial ischemia:  
  - Symptoms of acute myocardial ischemia  
  - New ischemic ECG changes  
  - Development of pathological Q waves  
  - Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology  
  - Identification of a coronary thrombus by angiography or autopsy (not for type 2 MI) |
| Type 1 MI                       | MI caused by atherothrombotic coronary artery disease and usually precipitated by atherosclerotic plaque disruption (rupture or erosion)        |
| Type 2 MI                       | MI caused by a mismatch between oxygen supply and demand by a pathophysiological mechanism other than coronary atherothrombosis (Type 1 MI)         |
| Acute Non-Ischemic Myocardial Injury | Acute myocardial injury (rise and/or fall in biomarkers [cTn]) in the absence of a primary ischemic cause (i.e., absence of MI)                  |
| Chronic Myocardial Injury      | Chronic myocardial injury (cTn >99th percentile URL without an acute change)                                                               |

cTn=cardiac troponin, URL=upper reference limit, ECG=electrocardiogram
Table 2. Prevalence and Mortality Associated with Type 1 MI, Type 2 MI, and Myocardial Injury

| First Author | Population and sample size | Prevalence % (n) | Mortality | Diagnostic Criteria |
|--------------|----------------------------|------------------|-----------|---------------------|
|              |                            | Proportion of all MIs |          |                     |
|              |                            | Type 1 MI | Type 2 MI | Non-Ischemic Myocardial injury | Type 1 MI | Type 2 MI | Non-Ischemic Myocardial injury |
|              |                            | Proportion of all elevated cTn |          |                     |
| Emergency Department | | | | | | |
| Sandoval⁹ | Single center 1640 patients with suspected acute coronary syndrome | 42% (74) | 58% (103) | 60% (254) | 180 days: 8% 2 years: 16% | 180 days: 13% 2 years: 22% | 180 days: 11% 2 years: 26% | Third Universal Definition of MI (2012) |
| Meigher¹⁰ | Single center 1283 patients with suspected acute coronary syndrome | 43% (340) | 57% (452) | 35.7% (458) | Index hospitalization: 11% | Index hospitalization: 12% | Index hospitalization: 7% | Third Universal Definition of MI (2012) |
| Nestelberger¹¹ | 12 centers 4015 patients with suspected acute coronary syndrome | 74% (684) | 26% (240) | 4% (172) | 90 days: 4.8% | 90 days: 1.7% | 90 days: 0.2% | Third Universal Definition of MI (2012) |
| Cediel¹² | Single center 1010 patients suspected of acute coronary syndrome and at least one elevated cTn | 66% (376) | 34% (194) | - | 2 years: 20% | 2 years: 40% | - | Third Universal Definition of MI (2012) |
| Neumann¹³ | 1548 patients suspected of acute coronary syndrome | 66% (188) | 34% (99) | - | 1 year: 9% | 1 year: 14% | - | Third Universal Definition of MI (2012) |

Non-MI conditions associated with elevated cTn excluded (e.g., myocarditis)
| First Author | Population and sample size | Prevalence % (n) | Mortality | Diagnostic Criteria |
|--------------|----------------------------|------------------|-----------|---------------------|
|              |                            | Proportion of all MIs | Proportion of all elevated cTn | Type 1 MI | Type 2 MI | Non-Ischemic Myocardial injury |
|              |                            | Type 1 MI | Type 2 MI | Type 1 MI | Type 2 MI | Non-Ischemic Myocardial injury |
|              |                            | Index hospitalization: 7% 30 days: 9% 1 year: 17% | Index hospitalization: 19% 30 days: 24% 1 year: 44% 3.2 years: 63% | 3.2 years: 59% | Second Universal Definition of MI (2007) |
| Hospitalized Patients | | | | | | |
| Saaby\(^{14}\) | Single center 7230 patients with cTn measurement in Denmark | 72\% (397) | 26\% (144) | 1408 (72\%) | Index hospitalization: 7\% 30 days: 9\% 1 year: 17\% | Index hospitalization: 19\% 30 days: 24\% 1 year: 44\% 3.2 years: 63\% | 3.2 years: 59\% | Second Universal Definition of MI (2007) |
| Saaby\(^{15}\) | | | | | | | |
| Sarkisian\(^{16}\) | | | | | | | |
| Sarkisian\(^{17}\) | | | | | | | |
| Javed\(^{18}\) | Single center 2979 patients with elevated cTn concentrations | 66\% (143) | 30\% (64) | 15\% (461) | - | - | 14.5\% (in hospital) | Second Universal Definition of MI (2007) |
| Melberg\(^{19}\) | Single center 1093 patients with acute MI | 89\% (967) | 2\% (17) | - | - | - | Second Universal Definition of MI (2007) |
| Gonzalez\(^{20}\) | Single center 348 patients with acute MI | 80\% (278) | 16\% (55) | - | 2.5 years: 30\% | 2.5 years: 16\% | - | Second Universal Definition of MI (2007) |
| Stein\(^{21}\) | Single center 2818 patients with acute MI | 96\% (2691) | 5\% (127) | - | In hospital: 4\% 30 days: 5\% 1 year: 9\% | In hospital: 12\% 30 days: 14\% 1 year: 24\% | - | Second Universal Definition of MI (2007) |
| First Author | Population and sample size | Prevalence % (n) | Mortality | Diagnostic Criteria |
|--------------|-----------------------------|------------------|-----------|---------------------|
|              |                             | Proportion of all MIs | Proportion of all elevated cTn | Type 1 MI | Type 2 MI | Non-Ischemic Myocardial injury |
|              |                             | Type 1 MI | Type 2 MI | Non-Ischemic Myocardial injury | In hospital: 6% | In hospital: 29% | - |
| El-Haddad22  | Single center 807 patients with elevated cTn concentrations | 63% (512) | 37% (295) | - | In hospital: 6% | In hospital: 29% | - |
| Shah23       | Single center 2165 patients with elevated cTn concentrations | 73% (1171) | 27% (429) | 24% (522) | 1 year: 16% | 1 year: 31% | 1 year: 37% | 5 years: 37% | 5 years: 63% | 5 years: 72% | Third Universal Definition of MI (2012) |
| Chapman24    | Single center 2165 patients with elevated cTn concentrations | 73% (1171) | 27% (429) | 24% (522) | 1 year: 16% | 1 year: 31% | 1 year: 37% | 5 years: 37% | 5 years: 63% | 5 years: 72% | Third Universal Definition of MI (2012) |
| Smilowitz25  | Single center 768 patients with elevated cTn concentrations | 47% (137) | 50% (146) | 59% (420) | In hospital: 13% | In hospital: 12% | In hospital: 9% | 2 years: 30% | 2 years: 31% | 2 years: 30% | Third Universal Definition of MI (2012) |
| Smilowitz26  | Single center 1577 patients admitted with elevated cTn concentrations | 75% (360) | 25% (119) | 69% (1089) | 3.2 years: 32% | 3.2 years: 62% | 3.2 years: 59% | Second Universal Definition of MI (2007) |
| Intensive Care Unit |                             |                          |                          |                          |                          |                          |                          |
| Baron27      | All 73 hospitals in Sweden 20,138 patients with acute MI | 89% (17,488) | 7% (1403) | - | 1 year: 14% | 1 year: 25% | - | Third Universal Definition of MI (2012) |
| Clinical Trial Post ACS |                             |                          |                          |                          |                          |                          |                          |
| Morrow28     | TRITON TIMI 38 trial 1218 patients with recurrent MI | 33% (397) | 4% (43) | - | 180 days: 8% | 180 days: 7% | - | Second Universal Definition of MI (2007) |

MI=myocardial infarction, cTn=cardiac troponin
Type 1 and type 2 prevalence is proportion of all diagnosed acute MI.
Myocardial injury

Acute

Ischemic

Acute ischemic myocardial injury

Type 1 myocardial infarction

Non-ischemic

Acute non-ischemic myocardial injury

Type 2 myocardial infarction

Chronic myocardial injury

Chronic
This is a scatter plot illustrating the relationship between time from presentation to mortality assessment (years) and all-cause mortality (%). The plot distinguishes between Type 1 MI (red circles), Type 2 MI (blue circles), and Myocardial injury* (purple circles) based on the references listed on the graph:

- Saaby (15)
- Shah (23)
- Smilowitz (25)
- Gonzalez (20)
- El-Haddan (22)
- Stein (21)
- Baron (27)
- Sandoval (9)
- Meigher (10)
- Javed (18)
- Morrow (28)
- Nestelberger (11)

The x-axis represents the time from presentation to mortality assessment in years, ranging from 0 to 5 years. The y-axis represents all-cause mortality, ranging from 0% to 100%. The data points are color-coded by type of myocardial infarction, with red for Type 1 MI, blue for Type 2 MI, and purple for Myocardial injury*.
Evidence of myocardial Injury

Dynamic pattern of cTn elevation

Stable pattern of cTn elevation

Chronic Myocardial Injury
- Identify and treat underlying insult (e.g., renal failure, HF)
- Consider structural imaging (e.g., echo)

Assess initial probability of ischemic cause for the acute myocardial injury

High probability
- Decision based on data available at presentation
  - History and physical
  - ECG

Intermediate probability of ischemia

Low probability

Acute Non-Ischemic Myocardial Injury
- Identify and treat underlying insult (e.g., myocarditis)
- Consider structural imaging (e.g., echo, CMR)
- Evaluate need for CAD primary and secondary prevention therapy (consider ischemic assessment if CAD status unclear)

Initial evaluation and management strategy:
- Pre-test probability of type 1 MI vs. alternative causes of myocardial injury
- Risks of diagnostic testing
- Consider expected outcomes with or without treatment

See figure 5

Lower probability of Type 1 MI

Compelling evidence of supply/demand mismatch

Culprit coronary lesion* identified

Type 2 MI
- Identify and treat underlying insult (e.g., coronary spasm or dissection, tachyarrhythmia)
- Initiate CAD prevention

Type 1 MI
- Interventional, surgical, and medical therapy per acute MI guidelines

Coronary imaging indicated

Coronary imaging contraindicated or deferred

Clinical diagnosis without imaging

* Culprit lesion in this context refers to a lesion causal of MI (e.g., plaques disruption and atherothrombosis). See text for discussion of the limitations of angiographic determination of culprit lesions.

** UDMI classifies MI as a result of coronary spasm, dissection, or embolization as Type 2
Pre-test probability of Type 1 MI

Absence of ischemic symptoms
Acute medical illness or recent surgery
Non-diagnostic ECG
Borderline cTn elevation

Likely ischemic symptoms
No clear triggers for type 2 MI
Known CAD
ST elevation
Very high cTn
Large cTn change over serial measurements

Risk of investigation and treatment

Anemia
Impaired renal function
Anticoagulant therapy
Previous stroke
Previous GI bleed
Chronic NSAID use
Frail
Peptic ulcer disease
Drug or alcohol abuse

Initial strategy
Conservative
Single or no antiplatelet

Further investigation and treatment
No additional acute cardiac testing required
Single or no antiplatelet

Non-invasive cardiac testing
Dual antiplatelet therapy
Parenteral anticoagulant
Coronary angiography
Dual antiplatelet therapy
Parenteral anticoagulant
Coronary angiography +/− PCI

Normal hemoglobin
Normal creatinine
Invasive